Clinical Trial COGANBL12P1


Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma

Principal Investigator(s)

Haydar Frangoul


  • Protocol No. COGANBL12P1
  • Open Date: 06/05/2013
  • Staging: Pilot
  • Age Group: Both Child and Adult
  • Scope: National
  • Objective: To determine if the acute toxicity of an autologous stem cell transplant with a busulfan/melphalan (BuMel) based regimen is tolerable when given as Consolidation therapy for high-risk neuroblastoma.
  • Disease Sites: Neuroblastoma (Pediatrics)
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Cisplatin; Cyclophosphamide (CTX); Doxorubicin; Etoposide; Topotecan (parenteral) IV; Vincristine
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01798004
  • Secondary Protocol No: ANBL12P1



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.